Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
about
The use and misuse of positron emission tomography in lung cancer evaluationThe role of induction therapy in the management of resectable non-small cell lung cancer.Targeting the eicosanoid pathway in non-small-cell lung cancer.Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospects.Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer.Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective.Chemotherapy in non-small cell lung cancer: time to re-examine our attitudesImmunotherapy in surgically resectable non-small cell lung cancer.
P2860
Q27021838-BEFA2699-4D45-47E4-92B7-888C84C7C9C7Q33877447-C5E9673C-47A6-4AAE-BDAD-E3C123BA7280Q33936807-78099C83-41B6-40BD-8FB1-F41EFD6DD8CFQ35143926-08DB567B-5AAC-4836-B828-123228CFC76BQ36035786-74811AB4-C06C-49A6-9FCF-E7812887BE7CQ36194573-DBEE71F8-10EA-427A-AEB0-C21579946A1BQ36525431-65EF0C8F-D8D7-407C-89C2-6A7376827297Q36752521-33F702FC-3B5B-4F8D-B854-A2D839A82E7EQ40405752-798A6BE0-7674-439A-83F8-F6F1B448DF13Q40636438-C106AA19-A382-43A2-9CA0-D703B55B0598Q41016175-BD42FCB9-6317-49B8-BD19-7A819A3AC06BQ42731118-64CC6700-76C5-45F8-827C-0141A06E4F83Q52624364-531E533C-65C9-4C6F-9ED3-6565E0E3895B
P2860
Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Pathologic complete response i ...... ncer combined modality trials.
@en
type
label
Pathologic complete response i ...... ncer combined modality trials.
@en
prefLabel
Pathologic complete response i ...... ncer combined modality trials.
@en
P2093
P1476
Pathologic complete response i ...... ncer combined modality trials.
@en
P2093
P304
P356
10.1200/JCO.1993.11.9.1757
P407
P577
1993-09-01T00:00:00Z